STAT3 Inhibitor WP1066 As a Novel Therapeutic Agent for Renal Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 May 13

PMID 20461084

Citations 69

Authors

A Horiguchi

K Kuroda

A Sato

J Asakuma

K Ito

M Hayakawa

M Sumitomo

T Asano

Affiliations

Soon will be listed here.

Abstract

Background: Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes that mediate cell survival, proliferation, and angiogenesis and is aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC). We examined whether it could be a novel therapeutic target for RCC by using the STAT3 inhibitor WP1066.

Methods: The antitumour activities and related mechanisms of WP1066 were investigated in vitro on renal cancer cell lines and in vivo on murine xenografts.

Results: In Caki-1 and 786-O renal cancer cells, 5 muM WP1066 prevented the phosphorylation of STAT3, and 2.5 muM WP1066 significantly (P<0.01) inhibited cell survival and proliferation. WP1066 suppressed the expression of Bcl-2, induced apoptosis, and inhibited the basal and hypoxia-induced expression of HIF1alpha and HIF2alpha, as well as vascular endothelial growth factor secretion into cell culture medium. Human umbilical vascular endothelial cells cocultured with media from WP1066-treated cells showed significantly reduced tubulogenesis (P<0.05). Systemic oral administration of WP1066 to mice for 19 days significantly inhibited the growth of Caki-1 xenograft tumours (P<0.05), and pathological analysis of xenografts of WP1066-treated mice showed decreased immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels (P<0.05).

Conclusion: Our results suggest that using WP1066 to inhibit the STAT3 signalling pathway could be a novel therapeutic strategy against RCC.

Citing Articles

Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives.

Soroush A, Pourhossein S, Hosseingholizadeh D, Hjazi A, Shahhosseini R, Kavoosi H Med Oncol. 2024; 41(5):125.

PMID: 38652207 DOI: 10.1007/s12032-024-02327-3.

Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance.

Schelz Z, Muddather H, Zupko I Antibiotics (Basel). 2023; 12(9).

PMID: 37760764 PMC: 10525194. DOI: 10.3390/antibiotics12091468.

STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors.

Golus M, Bugajski P, Chorbinska J, Krajewski W, Leminski A, Saczko J Cells. 2022; 11(19).

PMID: 36230984 PMC: 9563420. DOI: 10.3390/cells11193024.

Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.

Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T Cells. 2022; 11(16).

PMID: 36010693 PMC: 9406645. DOI: 10.3390/cells11162618.

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy.

Hersh A, Gaitsch H, Alomari S, Lubelski D, Tyler B Cancers (Basel). 2022; 14(15).

PMID: 35954407 PMC: 9367289. DOI: 10.3390/cancers14153743.

References

Jung J, Lee H, Cho I, Chung D, Yoon S, Yang Y . STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005; 19(10):1296-8. DOI: 10.1096/fj.04-3099fje. View

Aggarwal B, Kunnumakkara A, Harikumar K, Gupta S, Tharakan S, Koca C . Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci. 2009; 1171:59-76. PMC: 3141289. DOI: 10.1111/j.1749-6632.2009.04911.x. View

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S . Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005; 24(36):5552-60. DOI: 10.1038/sj.onc.1208719. View

Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M . Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 2006; 28(3):529-36. DOI: 10.1093/carcin/bgl143. View

Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A . Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer. 2009; 101(12):2005-14. PMC: 2795437. DOI: 10.1038/sj.bjc.6605437. View

Siddiquee K, Turkson J . STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008; 18(2):254-67. PMC: 2610254. DOI: 10.1038/cr.2008.18. View

Hussain S, Kong L, Jordan J, Conrad C, Madden T, Fokt I . A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007; 67(20):9630-6. DOI: 10.1158/0008-5472.CAN-07-1243. View

Campbell L, Nuttall R, Griffiths D, Gumbleton M . Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer. 2009; 115(15):3457-67. DOI: 10.1002/cncr.24389. View

Schindler C, Darnell Jr J . Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995; 64:621-51. DOI: 10.1146/annurev.bi.64.070195.003201. View

10.

Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T . Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995; 55(18):4182-7. View

11.

Motzer R, Rini B, Bukowski R, Curti B, George D, Hudes G . Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295(21):2516-24. DOI: 10.1001/jama.295.21.2516. View

12.

Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson K . Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer. 1996; 66(3):322-5. DOI: 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0. View

13.

Huang A, Fone P, Gandour-Edwards R, White R, Low R . Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol. 1999; 162(2):610-3. View

14.

Verstovsek S, Manshouri T, Quintas-Cardama A, Harris D, Cortes J, Giles F . WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008; 14(3):788-96. DOI: 10.1158/1078-0432.CCR-07-0524. View

15.

Huang S . Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007; 13(5):1362-6. DOI: 10.1158/1078-0432.CCR-06-2313. View

16.

Darnell Jr J . STATs and gene regulation. Science. 1997; 277(5332):1630-5. DOI: 10.1126/science.277.5332.1630. View

17.

Horiguchi A, Oya M, Marumo K, Murai M . STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. 2002; 61(3):926-38. DOI: 10.1046/j.1523-1755.2002.00206.x. View

18.

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

19.

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

20.

Amin H, McDonnell T, Ma Y, Lin Q, Fujio Y, Kunisada K . Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004; 23(32):5426-34. DOI: 10.1038/sj.onc.1207703. View